All In Biotech

Drug Trial Radar · NCT03493282

Effect of CT1812 Treatment on Brain Synaptic Density

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Mar 28, 2018

Primary completion

Oct 16, 2020

Study completion Oct 16, 2020

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA)
First posted
Apr 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

  • Active Treatment- CT1812 100 mgDrug

    CT1812

  • Active Treatment- CT1812 300 mgDrug

    CT1812

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of TEAEs, Related TEAEs, SAEs, and Related SAEsTime frame: Up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yale University School of Medicine

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.